Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.

Shannon Puhalla,Véronique Diéras,Banu Arun,Bella Kaufman,Hans Wildiers,Hyo S. Han,Jean-Pierre M. Ayoub,Vered Stearns,Yuan Yuan,Teresa Helsten,Bridget Riley-Gillis,Erin Murphy,Madan Gopal Kundu,Meijing Wu,David Maag,Christine K. Ratajczak,Cyril Ramathal,Michael Friedlander

Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.

2020

Shannon Puhalla
Véronique Diéras
Banu Arun
Bella Kaufman
Hans Wildiers
Hyo S. Han
Jean-Pierre M. Ayoub
Vered Stearns
Yuan Yuan
Teresa Helsten
Bridget Riley-Gillis
Erin Murphy
Madan Gopal Kundu
Meijing Wu
David Maag
Christine K. Ratajczak
Cyril Ramathal
Michael Friedlander

1097Background: In BROCADE3 (NCT02163694), addition of the PARP inhibitor (PARPi) V to CP improved PFS in patients (pts) with gBRCA-associated advanced breast cancer (hazard ratio 0.71 [95% CI 0.57...

Keywords:

Carboplatin/paclitaxel
Oncology
Breast cancer
in patient
Pathology
HER2 negative
Internal medicine
Veliparib
Biomarker (medicine)
Medicine
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations